Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs
Article first published online: 16 SEP 2014
© 2014 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Diabetes, Obesity and Metabolism
Volume 17, Issue 4, pages 430–434, April 2015
How to Cite
Yabe, D., Kuwata, H., Kaneko, M., Ito, C., Nishikino, R., Murorani, K., Kurose, T. and Seino, Y. (2015), Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes, Obesity and Metabolism, 17: 430–434. doi: 10.1111/dom.12381
- Issue published online: 11 MAR 2015
- Article first published online: 16 SEP 2014
- Accepted manuscript online: 22 AUG 2014 06:42AM EST
- Manuscript Accepted: 12 AUG 2014
- Manuscript Revised: 8 AUG 2014
- Manuscript Received: 11 MAR 2014
- Japan Society for Science Promotion
- Japan Association for Diabetes Education and Care
- Japan Vascular Disease Research Foundation
- acute pancreatitis;
- claims database;
- dipeptidyl peptidase-4 inhibitor
This study was initiated to evaluate the association of acute pancreatitis (AP) with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with diabetes in Japan. A retrospective cohort study of a large medical and pharmacy claims database was performed to compare the incidence of AP among those receiving DPP-4 inhibitors and those receiving other oral antidiabetic drugs. The incidence of all AP and hospitalizations for AP was similar between the two groups. Previous exposure to DPP-4 inhibitors did not affect occurrence of AP in patients on other oral antidiabetic drugs. The Kaplan–Meier curve for time to AP was similar between the two groups, and was not affected by previous exposure to DPP-4 inhibitors. The Cox proportional hazard models showed the incidence of AP was not significantly higher in those receiving DPP-4 inhibitors. Despite numerous, important limitations related to claims database-based analyses, our results indicate that there is no increased risk of AP with use of DPP-4 inhibitors among patients with diabetes in Japan.